Knight Therapeutics reports Q4 EPS (C$0.23) vs. (C$0.13) last year

Reports Q4 revenue C$74.2M vs. C$81.7M last year. “I am excited to announce that we have delivered ten consecutive years of record revenues and have delivered record EBITDA since 2019. For 2023, we reported revenues of over $343 million, a growth of 18%, and adjusted EBITDA of over $60 million, a growth of 11%. While delivering on record results, we made significant progress in advancing and expanding our product pipeline. We submitted five products, Minjuvi, Pemazyre, Tavalisse, Rembre and Karfib, for regulatory approval across multiple territories and received the regulatory approval of Minjuvi in Brazil, Palbocil and Xetrane in Chile and Karfib in Colombia. In addition, we are launching four products, Imvexxy and Bijuva in Canada, Minjuvi in Brazil and Palbocil in Argentina. Further to advancing our product pipeline, we expanded our portfolio with the in-licensing of three additional products, a branded generic molecule in Oncology/Hematology for Brazil, QelbreeTM for Canada and IPX203 for Canada and Latin America. Looking ahead we will remain focused on our strategy of building a profitable pan-American company commercializing both innovative and branded generic pharmaceuticals products. With our strong foundation and unique platform, we are poised to be the partner of choice for Canada and Latin America,” said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.